Can a 16-year-old receive Menveo (Meningococcal conjugate vaccine), HPV (Human Papillomavirus vaccine), and influenza vaccines simultaneously?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can a 16-Year-Old Receive Menveo, HPV, and Influenza Vaccines Simultaneously?

Yes, a 16-year-old can and should receive Menveo (MenACWY), HPV vaccine, and influenza vaccine at the same visit without any safety concerns or reduced immunogenicity. 1

Guideline Support for Simultaneous Administration

The Advisory Committee on Immunization Practices (ACIP) explicitly recommends simultaneous administration of all vaccines for which a person is eligible, including both live and inactivated vaccines, when no specific contraindications exist. 1 This applies directly to the three vaccines in question:

  • All three vaccines are inactivated vaccines (Menveo is a conjugate vaccine, HPV is a recombinant vaccine, and influenza is typically an inactivated vaccine), which can be administered together without any spacing requirements. 1

  • No immunologic interference occurs when these vaccines are given concomitantly. 2

Age-Appropriate Recommendations

At age 16, all three vaccines are specifically recommended:

  • MenACWY (Menveo): A booster dose is recommended at age 16 years if the adolescent received their first dose at age 11-12 years. 3, 4

  • HPV vaccine: Routine vaccination is recommended for adolescents aged 13-26 years if not previously vaccinated, with the preferred age range being 11-21 years for males and 11-26 years for females. 5

  • Influenza vaccine: Annual vaccination is recommended for all persons aged 6 months and older, including adolescents. 6

Evidence from Clinical Trials

A randomized, open-label study specifically evaluated coadministration of HPV vaccine with Tdap and/or meningococcal conjugate vaccine (MCV4, which is the same class as Menveo) in girls aged 11-18 years. 2 The study demonstrated:

  • Noninferiority criteria were met for all immunogenicity endpoints when vaccines were coadministered versus given separately. 2

  • No differences in reactogenicity were observed whether HPV vaccine was given alone or with meningococcal conjugate vaccine. 2

  • Seroconversion rates and antibody titers to HPV antigens were similar regardless of coadministration. 2

Practical Administration Guidelines

When administering these three vaccines simultaneously:

  • Give each vaccine at a different anatomical site, preferably in different limbs. 1

  • Administer the full recommended dose of each vaccine; do not use reduced volumes. 1

  • Document all vaccines properly to maintain accurate immunization records. 1

Key Benefits of Simultaneous Administration

  • Increases vaccination coverage by reducing missed opportunities, which is particularly important given that substantial missed opportunities remain for vaccinating adolescents. 4

  • Reduces the number of clinic visits required, improving convenience and compliance. 1

  • Critical when uncertainty exists about whether the patient will return for future doses. 1

Common Pitfalls to Avoid

  • Do not delay any vaccine unnecessarily—there is no medical reason to separate these vaccines. 1

  • Do not confuse spacing rules—the 4-week spacing rule applies only between live vaccines, not between inactivated vaccines or between inactivated and live vaccines. 1

  • Do not miss the opportunity to administer all age-appropriate vaccines during a single visit, as ACIP specifically recommends this approach. 4

Safety Profile

  • No serious adverse reactions have been observed with simultaneous administration of these vaccine types. 1, 2

  • Similar rates of local reactions are observed whether vaccines are given together or separately. 1

  • The most common adverse events are injection-site reactions and mild systemic symptoms, which occur at similar rates regardless of coadministration. 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.